Experimental cancer combo shows early promise but trial halted

NCT ID NCT02936102

Terminated Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called FAZ053, alone or with another drug (PDR001), in 154 adults with advanced solid tumors. The goal was to check safety and find the right dose by boosting the immune system to attack cancer. The study was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FAZ053 (anti-PD-L1 antibody) and PDR001 (anti-PD-1 antibody)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors by boosting the immune system to fight cancer.
What could go wrong: This is a very early Phase 1 trial focused on safety, not effectiveness. The study was terminated early, so results may be limited. Immune-related side effects can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alveolar soft part sarcoma chordoma neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CHORDOMA AND ALVEOLAR SOFT PART SARCOMA TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Ctr

New York, New York, 10065, United States
Novartis Investigative Site

Toronto, Ontario, M5G 2M9, Canada
Novartis Investigative Site

Toulouse, 31059, France
Novartis Investigative Site

Tel Aviv, 6423906, Israel
Novartis Investigative Site

Milan, MI, 20133, Italy
Novartis Investigative Site

Modena, MO, 41124, Italy
Novartis Investigative Site

Koto Ku, Tokyo, 135 8550, Japan
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Seville, Andalusia, 41013, Spain
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Taipei, 10002, Taiwan
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.